Recruitment of Pontin/Reptin by E2f1 amplifies E2f transcriptional response during cancer progression

Amy Tarangelo, Nathanael Lo, Rebecca Teng, Eunsun Kim, Linh Le, Deborah Watson, Emma E. Furth, Pichai Raman, Ursula Ehmer and Patrick Viatour ()
Additional contact information
Amy Tarangelo: Center for Childhood Cancer Research, Children’s Hospital of Philadelphia
Nathanael Lo: Center for Childhood Cancer Research, Children’s Hospital of Philadelphia
Rebecca Teng: Center for Childhood Cancer Research, Children’s Hospital of Philadelphia
Eunsun Kim: Center for Childhood Cancer Research, Children’s Hospital of Philadelphia
Linh Le: Center for Childhood Cancer Research, Children’s Hospital of Philadelphia
Deborah Watson: Children’s Hospital of Philadelphia
Emma E. Furth: Perelman School of Medicine, University of Pennsylvania
Pichai Raman: Children’s Hospital of Philadelphia
Ursula Ehmer: University Hospital of Munich
Patrick Viatour: Center for Childhood Cancer Research, Children’s Hospital of Philadelphia

Nature Communications, 2015, vol. 6, issue 1, 1-14

Abstract: Abstract Changes in gene expression during tumorigenesis are often considered the consequence of de novo mutations occurring in the tumour. An alternative possibility is that the transcriptional response of oncogenic transcription factors evolves during tumorigenesis. Here we show that aberrant E2f activity, following inactivation of the Rb gene family in a mouse model of liver cancer, initially activates a robust gene expression programme associated with the cell cycle. Slowly accumulating E2f1 progressively recruits a Pontin/Reptin complex to open the chromatin conformation at E2f target genes and amplifies the E2f transcriptional response. This mechanism enhances the E2f-mediated transactivation of cell cycle genes and initiates the activation of low binding affinity E2f target genes that regulate non-cell-cycle functions, such as the Warburg effect. These data indicate that both the physiological and the oncogenic activities of E2f result in distinct transcriptional responses, which could be exploited to target E2f oncogenic activity for therapy.

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms10028 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms10028

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms10028

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().